RAPGEF3

Across TCGA pan-cancer cohorts, RAPGEF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAPGEF3 data layer compared with 19 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAPGEF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAPGEF3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where RAPGEF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.917	0.469	.004	45	view →
LUAD	DFS	Tertile	III,IV	0.286	0.986	.024	14	view →
PDAC	DFS	Median	II,III,IV	0.226	0.840	.006	12	view →
UCEC	DFS	Median	All	0.576	0.943	.001	12	view →
HNSC	DFS	Median	III,IV	1.000	0.740	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAPGEF3–CCRCC (DFS)

Open the CCRCC breakdown →